Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) said it will report first quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026.
Management will review the results on a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the company Investors page, with replay accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) announced clinical data presentations for its OMNI Surgical System and TearCare System at the 2026 ASCRS Annual Meeting in Washington, DC on April 11. According to the company, OMNI data show reduced long-term diurnal IOP fluctuations regardless of lens status, while TearCare data report early and sustained superiority over Restasis for tear film stability.
Presentations include TearCare oral and poster sessions on April 11 and an OMNI poster on longer-term diurnal IOP following canaloplasty and trabeculotomy; lead and presenting authors are named.
Sight Sciences (Nasdaq: SGHT) will present at the 25th Annual Needham Healthcare Conference on Monday, April 13, 2026 at 11:15 am PT / 2:15 pm ET. Management will deliver a fireside chat available via live and archived webcast.
Investors can access the webcast on the company’s Investors website for a live stream and later replay.
Sight Sciences (Nasdaq: SGHT) announced a U.S. District Court order (entered March 27, 2026) that preserved a jury verdict finding Alcon willfully infringed three Sight Sciences patents and awarded monetary damages in excess of $34 million.
The order also provides an ongoing royalty of 10% of Hydrus revenue through November 10, 2028. A final judgment will follow after supplemental damages and pre-judgment interest are calculated; the judgment is subject to appeal and USPTO reexamination. The company expects a $5.4 million success fee to operating expenses payable to its counsel.
Sight Sciences (Nasdaq: SGHT) reported Q4 2025 revenue of $20.4M (+7% YoY) and full-year 2025 revenue of $77.4M (‑3% YoY). Gross margin was 87% in Q4 and 86% for FY2025. Adjusted operating expenses fell 13% year-over-year. Cash totaled $92.0M at year-end. The company provided 2026 guidance of $82M–$88M revenue and adjusted operating expenses of $93M–$96M.
Management cited commercial traction in glaucoma and dry eye and a pathway toward cashflow breakeven.
Sight Sciences (Nasdaq: SGHT) will report fourth quarter and full year financial results for the period ended December 31, 2025 after market close on Wednesday, March 4, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET and a live webcast and archived replay will be available on the company's Investors page. The replay will be accessible for at least 90 days.
Sight Sciences (Nasdaq: SGHT) provided preliminary, unaudited Q4 and full-year 2025 financial highlights for the period ended December 31, 2025. Q4 2025 revenue is expected to be $20.3M–$20.4M (≈+7% at midpoint). Full-year 2025 revenue is expected to be $77.3M–$77.4M (≈-3% at midpoint). Q4 Dry Eye revenue is ~$0.7M (+~130% YoY); full-year Dry Eye revenue is ~$1.6M vs $4.0M in 2024. Cash and cash equivalents were approximately $92M at Dec 31, 2025; cash used in 2025 totaled ~$28M. Results are preliminary and subject to audit with final results expected in March 2026.
Sight Sciences (NASDAQ: SGHT) reported three peer‑reviewed publications (Nov 1–Nov 11, 2025) showing the OMNI surgical system with TruSync technology lowers intraocular pressure (IOP) and medication use in cataract-combination and standalone glaucoma procedures, including analyses in African American patients.
Key results: a 24‑month prospective cohort (n=18) showed mean IOP 26.1 mmHg reduced by 9.7 mmHg at 12 months and 10.6 mmHg at 24 months, medications fell from 1.8 to 0.5 by 24 months, with two‑thirds medication‑free at Month 24. A ~13,000‑eye IRIS registry analysis found the highest ≥20% IOP reduction rate with OMNI among MIGS devices. A 220‑eye subgroup showed IOP reduction up to 3 years regardless of lens status or severity.
Sight Sciences (Nasdaq: SGHT) reported Q3 2025 results and raised full‑year guidance on Nov 6, 2025. Q3 revenue was $19.9M (‑1% YoY) with Surgical Glaucoma revenue of $19.7M (+6% YoY) and Dry Eye revenue of $0.2M (‑88% YoY). Gross profit was $17.2M and gross margin improved to 86%. Q3 adjusted operating expenses fell to $19.8M (‑17% YoY) and GAAP operating expenses were $25.1M, which included $2.8M of restructuring charges.
The company raised 2025 revenue guidance to $76.0M–$78.0M and cut adjusted operating expense guidance to $90M–$92M. Cash was $92.4M and long‑term debt $40.0M as of Sept 30, 2025.
Sight Sciences (Nasdaq: SGHT) announced the appointments of Alison (Ali) Bauerlein as Chief Operating Officer and James (Jim) Rodberg as Chief Financial Officer, effective November 5, 2025.
The company said the new COO role will support scaling reimbursed interventional dry eye and MIGS commercial efforts. Bauerlein joins the executive team after serving as Sight Sciences CFO since April 2023 and previously helped scale Inogen to over $350 million in annual sales. Rodberg was promoted from VP of Finance and corporate controller, has 20 years of finance and accounting experience and served as interim CFO in 2023.
The board also reported that Erica Rogers (six years) and Brenda Becker (three years) have stepped down from the board.